{"4YL.F": {"short_name": "NANOFORM FINLAND OYJ", "long_name": "Nanoform Finland Oyj", "summary": "Nanoform Finland Oy provides nanotechnology and drug particle engineering services for the pharmaceutical and biotechnology industries in Finland and internationally. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients in the creation of active pharmaceutical ingredients nanoparticles directly from solution. Its technology and services help in increasing the bioavailability of drug molecules and developing new drugs. The company was founded in 2015 and is headquartered in Helsinki, Finland.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Finland", "city": "Helsinki"}, "BIOBV.HE": {"short_name": "Biohit Oyj B", "long_name": "Biohit Oyj", "summary": "Biohit Oyj, a biotechnology company, produces diagnostic tests and analysis systems for use in research institutions and healthcare industries worldwide. Its diagnostic tests product range includes the GastroPanel test for diagnosing diseases of the stomach and associated risks; Biohit Active B12, a test for measuring the levels of active vitamin B12; Biohit Total, an indicator of vitamin D status; Biohit Calprotectin, a test for measuring human calprotectin; Helicobacter Pylori Quick Test and Helicobacter Pylori UFT300 Quick Test, a test methods to detect H. pylori infection from a biopsy sample during gastroscopy; ColonView Quick Test, a test for detection of fecal occult blood; Lactose Intolerance Quick Test; Celiac Disease Quick Test; and The GA-map Dysbiosis test, a gut microbiota DNA analysis tool. The company also provides monoclonal antibodies for use in cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, it provides acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenges, which removes acetaldehyde in smoker's saliva. Additionally, it provides microplate readers and strip washers, quick test readers, and ThunderBolt, an automated immunoassay analyzer; and products that bind carcinogenic acetaldehyde into harmless compounds, monoclonal antibodies, and service laboratory services. The company was founded in 1988 and is headquartered in Helsinki, Finland.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HEL", "market": "fi_market", "country": "Finland", "city": "Helsinki"}, "FARN.L": {"short_name": "FARON PHARMACEUTICALS OY ORD NP", "long_name": "Faron Pharmaceuticals Oy", "summary": "Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.", "currency": "GBp", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "LSE", "market": "gb_market", "country": "Finland", "city": "Turku"}, "FARON.HE": {"short_name": "Faron Pharmaceuticals Oy", "long_name": "Faron Pharmaceuticals Oy", "summary": "Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HEL", "market": "fi_market", "country": "Finland", "city": "Turku"}, "FPHAF": {"short_name": "FARON PHARMACEUTICALS OY", "long_name": "Faron Pharmaceuticals Oy", "summary": "Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Finland", "city": "Turku"}, "HRNTS.ST": {"short_name": "Herantis Pharma Oyj", "long_name": "Herantis Pharma Oyj", "summary": "Herantis Pharma Oyj, a drug development company, focuses on developing regenerative medicine. Its products in pipeline includes CDNF, which is in Phase I-II clinical trial for the treatment of Parkinson's disease, as well as in preclinical stage for the treatment of amyotrophic lateral sclerosis; and Lymfactin, which is in Phase II clinical trial for the treatment of breast cancer associated lymphedema. The company was founded in 2008 and is based in Espoo, Finland.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Finland", "city": "Espoo"}, "HRTIS.HE": {"short_name": "Herantis Pharma Oyj", "long_name": "Herantis Pharma Oyj", "summary": "Herantis Pharma Oyj, a drug development company, focuses on developing regenerative medicine. Its products in pipeline includes CDNF, which is in Phase I-II clinical trial for the treatment of Parkinson's disease, as well as in preclinical stage for the treatment of amyotrophic lateral sclerosis; and Lymfactin, which is in Phase II clinical trial for the treatment of breast cancer associated lymphedema. The company was founded in 2008 and is based in Espoo, Finland.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HEL", "market": "fi_market", "country": "Finland", "city": "Espoo"}, "NANOFS.ST": {"short_name": "Nanoform Finland Oyj", "long_name": "Nanoform Finland Oyj", "summary": "Nanoform Finland Oy provides nanotechnology and drug particle engineering services for the pharmaceutical and biotechnology industries in Finland and internationally. The company provides nanoparticle production services using its proprietary controlled expansion of supercritical solutions technology that enables clients in the creation of active pharmaceutical ingredients nanoparticles directly from solution. Its technology and services help in increasing the bioavailability of drug molecules and developing new drugs. The company was founded in 2015 and is headquartered in Helsinki, Finland.", "currency": "SEK", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "STO", "market": "se_market", "country": "Finland", "city": "Helsinki"}}